Ann: Regeneus receives R&D tax incentive refund of $3.4m, page-6

Hi dnc,

I'm no analyst but I've seen far worse companies with lesser product pipelines, and fewer products, with market caps 5 or 6 + times greater than RGS. So 50c is not unachievable. Personally I think the stem cell and immuno oncology space is appealing at the moment. The direction Japan is taking is interesting and I'm keen to be in position given potential short term catalysts for this stock. Partnering will be key for this business IMO so if we can secure something within the next 6 months we will be laughing.